SCHEMBL970559

SCHEMBL970559

Brc1ccc(-c2cnc(-c3ccccc3)nn2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.62
RAB9A P51151 4/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
NFKB1 P19838 2/20 0.62
NFKB2 Q00653 2/20 0.62
RELA Q04206 2/20 0.62
MAPK1 P28482 2/20 0.48
ALDH1A1 P00352 2/20 0.48
NR1H4 Q96RI1 1/20 0.46
DGAT1 O75907 1/20 0.44
NR1H2 P55055 1/20 0.44
NR1H3 Q13133 1/20 0.44
NLRP3 Q96P20 1/20 0.42
AGTR1 P30556 1/20 0.42
METAP2 P50579 1/20 0.42
MAOB P27338 1/20 0.41
PTGES O14684 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26569790 0.89 NPC1 (0.56) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL28242771 0.84 MET (0.46) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL17190530 0.82 MEN1 (0.58) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL17301594 0.82 MEN1 (0.58) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL28105486 0.81 ALDH1A1 (0.61) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL22449167 0.80 CLK4 (0.46) NPC1RAB9ASMN1; SMN2MAPK1ALDH1A1
SCHEMBL28104974 0.78 ALDH1A1 (0.64) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL3781325 0.77 NPC1 (1.00) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL15684061 0.77 NPC1 (1.00) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL6266823 0.77 PTGES (0.44) NPC1RAB9ASMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7867629-B2 Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same IDEMITSU KOSAN CO., LTD. (JP) 2011-01-11 US disclosed
CN-101407492-A Nitrogen-containing heterocyclic derivative and organic electroluminescent element using same IDEMITSU KOSAN CO (JP) 2009-04-15 CN disclosed
CN-101219987-A Nitrogen-containing heterocyclic derivative and organic electroluminescent element using same IDEMITSU KOSAN CO (JP) 2008-07-16 CN disclosed
US-20060154105-A1 Nitrogenous heterocyclic derivative and organic elecrtroluminescent element employing the same IDEMITSU KOSAN CO., LTD. (JP) 2006-07-13 US disclosed
CN-1751024-A Nitrogen-containing heterocyclic derivative and organic electroluminescent element using same IDEMITSU KOSAN CO (JP) 2006-03-22 CN disclosed
EP-1582516-A1 NITROGENOUS HETEROCYCLIC DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154105-A1 Nitrogenous heterocyclic derivative and organic elecrtroluminescent element employing the same L1CAM, NOTCH1, NUDC NPC1 4231/4885RAB9A 2094/4885SMN1; SMN2 1021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.